Cnodes: The canadian network for observational drug effect studies

Open Medicine

Volumn 6, Issue 4, 2012, Pages 134-140

  Suissa, Samy ^a   Henry, David ^b   Caetano, Patricia ^c   Dormuth, Colin R ^d   Ernst, Pierre ^a   Hemmelgarn, Brenda ^e   LeLorier, Jacques ^f   Levy, Adrian ^g   Martens, Patricia J ^h   Paterson, J Michael ^b   Platt, Robert W ^a   Sketris, Ingrid ^g   Teare, Gary ⁱ  

^a MCGILL UNIVERSITY   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; ARTICLE; CANADA; COMMUNITY CARE; DRUG SURVEILLANCE PROGRAM; HUMAN; MEDICAL RECORD; MEDICATION THERAPY MANAGEMENT; METHODOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; RISK ASSESSMENT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CANADA; COMMUNITY NETWORKS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MEDICAL RECORD LINKAGE; MEDICATION THERAPY MANAGEMENT; ORGANIZATIONAL OBJECTIVES; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; RISK ASSESSMENT;

EID: 84870571023     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Strom BL, Carson JL, Morse ML, LeRoy AA. The computerized on-line Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance. Clin Pharmacol Ther 1985;38(4):359-364.
2. Slone D, Shapiro S, Miettinen OS. Case-control surveillance of serious illnesses attributable to ambulatory drug use. In: Colombo F, Shapiro S, Slone D, Tognoni G, editors. Epidemiological evaluation of drugs. Amsterdam: Elsevier/North Holland Biomedical Press; 1977. p 59-82.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-1205.
4. Bains N, Hunter D. Adverse reporting on adverse reactions. CMAJ 1999;160(3):350-351
5. Guess HA, West R, Strand LM, Helston D, Lydick EG, Bergman U, et al. Hospitalization for renal impairment among users and non-users of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada, 1983. In: Rainsford KD, Velo GP, editors. Side-effects of anti-inflammatory drugs. Part 2: Studies in major organ systems. Lancaster (PA): MTP Press; 1987. p 367-374.
6. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326(8):501-506.
7. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146(11):775-786.
8. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179(4):319-326.
9. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005;365(9453):82-93.
10. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-1644.
11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-2471.
12. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163(4):481-486.
13. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142(7):481-489.
14. Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf 2009;18(11):1016-1025.
15. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343(21):1520-1528.
16. Garcia Rodriguez LA, Perez-Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45(5):419-425.
17. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 2008;3(8):e3081.
18. Peters J, Mengersen K. Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof 2008;31(4):370-389.
19. Briefing document for endocrinologic and metabolic drugs advisory committee meeting of December 15, 2009. Drug substance: rosuvastatin calcium. Gaithersburg (MD): AstraZeneca; 2009. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/UCM193833.pdf (accessed 2012 June 26).
20. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010;31(11):1165-1177.
21. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, Kimmell SE, Hennessy S, editors. Pharmacoepidemiology. 5th ed. Malden (MA): Wiley; 2012. p 158-162.
22. Collet JP, Boivin JF, Spitzer WO. Bias and confounding in pharmacoepidemiology. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. Malden (MA): Wiley; 1994. p 609-627.
23. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011;8(5):e10011026.
24. Drugs and health products: lifecycle management. Ottawa: Health Canada; 2007. Available from: www.hc-sc.gc.ca/dhp-mps/homologation-licensing/model/life-cycle-vie-eng.php (accessed 2012 June 26).
25. Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):1-8.